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Purpose: The aims of this study were to compare the expression of sarcosine me-
tabolism-related proteins between invasive lobular carcinoma (ILC) and invasive 
ductal carcinoma (IDC) and to determine the implications of these results. Materi-
als and Methods: Tissue microarrays were constructed, containing 30 samples 
from normal breast tissue, 114 samples from patients with ILC, and 692 samples 
from patients with IDC. Immunohistochemical staining was performed to examine 
the expression of sarcosine metabolism-related proteins [glycine N-methyltransfer-
ase, sarcosine dehydrogenase, and l-pipecolic acid oxidase (PIPOX)]. Results: The 
sarcosine metabolic phenotype differed between ILC and IDC (p<0.001). In IDC, 
sarcosine metabolic phenotype was distributed as null type (61.7%)>low sarcosine 
type (30.4%)>high sarcosine type (5.0%)>intermediate type (2.9%). However, in 
ILC, the sarcosine metabolic phenotype was distributed as low sarcosine type 
(61.4%)>null type (32.5%)>intermediate type (5.3%)>high sarcosine type (0.9%). 
PIPOX showed higher expression in ILC than in IDC (p<0.001) and correlated 
with androgen receptor (AR) positivity (p=0.001) in ILC. Conclusion: Expression 
of sarcosine metabolism-related proteins differed between ILC and IDC. Low sar-
cosine type was the majority sarcosine metabolic phenotype of ILC. PIPOX expres-
sion was predominant in ILC and correlated with AR positivity.
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INTRODUCTION
Breast cancer is one of most common cancers in women and comprises about 
23% of all female carcinomas.1 With regard to histologic subtypes, invasive ductal 
carcinoma (IDC) and invasive lobular carcinoma (ILC) are the major two subtypes 
of invasive carcinoma of the breast.1 Among the various subtypes, ILC accounts 
for about 5‒15% of all invasive carcinomas,2,3 and the incidence of ILC has in-
creased more rapidly than that of IDC in the past decade due to widely-prescribed 
hormone replacement therapy and increasing alcohol consumption.4,5 ILC is dis-
tinguished from IDC by several clinical and histologic features. For example, ILC 
usually shows multifocal manifestation and tends to occur in both breasts simulta-
neously.6,7 Histologically, ILC is characterized by discohesive cancer cells lacking 
E-cadherin expression.8 Metastatic sites in ILC are often unusual regions including 
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lected at Severance Hospital. Tissue samples were obtained 
from patients who had undergone breast surgery due to 
ILC. For the control group, tissue samples were prepared 
from patients diagnosed with IDC, not otherwise specified 
from 2006 to 2010. This study was approved by the Institu-
tional Review Board of Severance Hospital. Patients who 
had received preoperative chemotherapy were excluded from 
this study. Histologic examination was performed by hema-
toxylin and eosin (H&E) staining, and all slides were re-
viewed retrospectively by a trained breast pathologist (Koo 
JS). The histologic grade was assessed using the Notting-
ham grading system.15 Tumor staging was based on the sev-
enth American Joint Committee on Cancer criteria. Disease-
free survival was calculated from the date of the first curative 
surgery to the date of the first loco-regional or systemic re-
lapse or to death without any type of relapse. Overall surviv-
al was estimated from the date of the first curative operation 
to the date of the last follow-up or death from any cause. 
Clinicopathologic parameters evaluated in each type of 
breast cancer included patient age at initial diagnosis, lymph 
node metastasis, tumor recurrence, distant metastasis, and 
patient survival.
 
Tissue microarray
Through retrospective review of the H&E-stained slides, 
the most appropriate FFPE tumor tissue samples were re-
trieved, and representative tumor areas were circled on the 
FFPE blocks. Two 3.0-mm tissue cores were taken from 
the representative region of each paraffin block and inserted 
into 6×5 recipient blocks.
Immunohistochemistry 
The antibodies used for immunohistochemistry in this 
the bones, gastrointestinal tract, uterus, meninges, and ova-
ries, which are rarely involved in cases of IDC.7,9,10 
Sarcosine (N-methylglycine) is a non-proteinogenic ami-
no acid that is made during the metabolism and catabolism 
of glycine. Several major enzymes involved in the sarco-
sine metabolism pathway include glycine N-methyltrans-
ferase (GNMT), sarcosine dehydrogenase (SARDH), and l-
pipecolic acid oxidase (PIPOX). GNMT participates in the 
production of sarcosine by transmitting the methyl group 
from S-adenosylmethionine to glycine. SARDH and PIPOX, 
both sarcosine-metabolizing enzymes, produce glycine 
from sarcosine by oxidative demethylation.11 Sarcosine has 
been reported as a potential oncometabolite more than non-
proteinogenic amino acid. In prostate cancer, sarcosine was 
studied as a sensitive tumor biomarker and was also found 
to have a relationship with tumor progression and the meta-
static process.12,13 Like prostate cancer, breast cancer is hor-
mone-dependent cancer, although in this case, it is predom-
inantly related to estrogen receptor (ER) and progesterone 
receptor (PR). However, androgen receptor (AR) is also ex-
pressed in breast cancer, especially in ILC.14 In contrast, the 
expression of sarcosine metabolism-related proteins in breast 
cancer remains to be elucidated. We aimed to investigate the 
expression of sarcosine metabolism-related proteins in ILC 
and IDC, to compare the expression rates in ILC and IDC, 
and to determine the implications of the results. 
MATERIALS AND METHODS
Patient selection and clinicopathologic evaluation
Between January 2000 and December 2012, formalin-
fixed, paraffin-embedded (FFPE) tissue samples were col-
Table 1. Source, Clone, and Dilution of Antibodies Used in This Study
Antibody Company Clone Dilution
Sarcosine metabolism-related
    GNMT Abcam, Cambridge, UK Polyclonal 1:100
    SARDH Abcam, Cambridge, UK Polyclonal 1:100
    PIPOX Abcam, Cambridge, UK Polyclonal 1:100
Molecular subtype-related
    ER Thermo Scientific, San Siego, CA, USA SP1 1:100
    PR DAKO, Glostrup, Denmark PgR 1:50
    HER-2 DAKO, Glostrup, Denmark Polyclonal 1:1500
    Ki-67 Abcam, Cambridge, UK MIB 1:1000
Androgen-related
    AR DAKO, Glostrup, Denmark AR441 1:150
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; ER, estrogen receptor; PR, progesterone receptor; 
AR, androgen receptor; HER-2, human epidermal growth factor receptor-2.
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negative breast cancer (TNBC) type: ER, PR, and HER-2 
negative. 
Sarcosine metabolism phenotypes
According to immunohistochemistry results for GNMT, 
SARDH, and PIPOX, sarcosine metabolism phenotypes 
were categorized as follows: high sarcosine type: GNMT 
(+), SARDH and PIPOX (-); low sarcosine type: GNMT (-), 
SARDH and/or PIPOX (+); intermediate sarcosine type: 
GNMT (+), SARDH or PIPOX (+); and null type: GNMT 
(-), SARDH and PIPOX (-).
Statistical analysis   
Data were statistically processed using SPSS for Windows 
version 12.0 (SPSS Inc., Chicago, IL, USA). Student’s t-test 
and Fisher’s exact test were used for continuous and cate-
gorical variables, respectively. Statistical significance was 
assumed when p<0.05. Kaplan-Meier survival curves and 
log-rank statistics were employed to evaluate time to sur-
vival. Multivariate regression analysis was performed using 
the Cox proportional hazards model.
RESULTS
 
Basal characteristics of invasive lobular carcinoma
The clinicopathologic characteristics of patients with ILC 
are summarized in Table 2. There were 114 patients with 
ILC, subdivided into 102 classic-type and 12 pleomorphic-
type patients. The pleomorphic type showed significant as-
sociation with older age (p=0.033), a higher nuclear grade 
(p<0.001), a higher histologic grade (p<0.001), a higher T 
stage (p=0.026), PR negativity (p=0.005), HER-2 positivity 
(p=0.002), a higher Ki-67 LI (p<0.001), and the non-lumi-
nal A subtype (p<0.001) compared with the classic type.
When comparing clinicopathologic parameters of ILC 
with those of IDC, ILC was associated with a lower histolog-
ic grade (p<0.001), no lymph node metastasis (p=0.026), ER 
positivity (p<0.001), PR positivity (p<0.001), HER-2 nega-
tivity (p<0.001), a lower Ki-67 LI (p<0.001), and a higher in-
cidence of luminal A type (p<0.001) (Table 3).
Expression of sarcosine metabolism-related proteins in 
normal tissue, ILC, and IDC 
No difference was observed in the expression of sarcosine 
metabolism-related proteins between the subtypes of ILC, 
although expressions of SARDH and PIPOX were higher 
study are shown in Table 1. Three-micrometer paraffin sec-
tions were deparaffinized and rehydrated by xylene and al-
cohol solution. Immunohistochemistry was performed us-
ing a Ventana Discovery XT automated staining system 
(Ventana Medical System, Tucson, AZ, USA). Antigen re-
trieval was performed using CC1 buffer [Cell Conditioning 
1; citrate buffer (pH 6.0), Ventana Medical System]. Appro-
priate positive and negative controls for immunohistochem-
ical staining were also included.
Interpretation of immunohistochemical results
A cut-off value of 1% or more positively-stained nuclei was 
used to define ER and AR positivity.16 Human epidermal 
growth factor receptor-2 (HER-2) staining was analyzed ac-
cording to the American Society of Clinical Oncology/Col-
lege of American Pathologists guidelines using the following 
categories: 0=no immunostaining; 1+=weak incomplete 
membranous staining in less than 10% of tumor cells; 
2+=complete membranous staining either uniform or weak 
in at least 10% of tumor cells; and 3+=uniform intense mem-
branous staining in at least 30% of tumor cells.17 HER-2 im-
munostaining was considered positive when strong (3+) 
membranous staining was observed whereas cases with 0 to 
1+ staining were regarded as negative. The cases showing 2+ 
HER-2 expression were evaluated for HER-2 amplification 
by fluorescent in situ hybridization (FISH).
Immunohistochemical markers for GNMT, SARDH, and 
PIPOX were accessed by light microscopy. Interpretation 
of immunohistochemical staining for autophagy and redox-
related proteins was determined by multiplying the propor-
tion of stained cells (0%=0; 1‒29%=1; 30‒100%=2) by the 
immunostaining intensity (negative=0; weak=1; moder-
ate=2; strong=3). Final scores of 0‒1 were interpreted as 
negative, and scores of 2‒6 were considered positive.18 The 
Ki-67 labeling index (LI) was scored by percentage of nu-
clear stained cells in total tumor cells (0‒100%).
Tumor phenotype classification
In this study, we classified breast cancer phenotypes accord-
ing to the immunohistochemistry results for ER, PR, HER-
2, and Ki-67 LI. FISH results for HER-2 were classified as 
follows:19 luminal A type: ER and/or PR positive, HER-2 
negative, and Ki-67 LI<14%; luminal B type: (HER-2 nega-
tive) ER and/or PR positive, HER-2 negative, and Ki-67 
LI≥14% and (HER-2 positive) ER and/or PR positive and 
HER-2 overexpressed or amplified; HER-2 type: ER and 
PR negative and HER-2 overexpressed or amplified; triple-
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sarcosine metabolism-related proteins showed different dis-
tributions among normal breast tissue, IDC, and ILC (Table 
7). Sarcosine metabolic phenotypes of normal breast tissue 
were null type (93.3%) and low sarcosine type (6.7%). In 
IDC, sarcosine metabolic phenotypes were composed of 
null type (61.7%)>low sarcosine type (30.4%)>high sarco-
sine type (5.0%)>intermediate type (2.9%); however, in 
ILC, the proportion of sarcosine metabolic phenotypes was 
low sarcosine type (61.4%)>null type (32.5%)>intermedi-
ate type (5.3%)>high sarcosine type (0.9%) (p<0.001). 
in ILC compared to normal tissue (SARDH: p=0.014; 
PIPOX: p<0.001) (Table 4). When comparing ILC with 
IDC, ILC showed a higher expression of PIPOX (p< 
0.001) (Table 5, Fig. 1). This difference of expression was 
also observed between ILC and IDC luminal types 
(p<0.001) (Table 6). 
Comparison of sarcosine metabolism phenotypes 
among normal tissue, IDC, and ILC
Sarcosine metabolic phenotypes based on the expression of 
Table 2. Clinicopathologic Characteristics of Invasive Lobular Carcinoma 
Parameters Total, n=114 (%)
Classic type, 
n=102 (%)
Pleomorphic type, 
n=12 (%) p value
Age (yrs) 0.033
    <50   63 (55.3) 60 (58.8)   3 (25.0)
    ≥50   51 (44.7) 42 (41.2)   9 (75.0)
Nuclear grade <0.001
    1/2 102 (89.5) 102 (100.0) 0 (0.0)
    3   12 (10.5) 0 (0.0)   12 (100.0)
Histologic grade <0.001
    I/II 109 (95.6) 102 (100.0)   7 (58.3)
    III   5 (4.4) 0 (0.0)   5 (41.7)
T stage 0.026
    T1   67 (58.8) 64 (62.7)   3 (25.0)
    T2/T3   47 (41.2) 38 (37.3)   9 (75.0)
Lymph node metastasis 0.749
    Absent   80 (70.2) 72 (70.6)   8 (66.7)
    Present   34 (29.8) 30 (29.4)   4 (33.3)
ER 0.158
    Negative   7 (6.1) 5 (4.9)   2 (16.7)
    Positive 107 (93.9) 97 (95.1) 10 (83.3)
PR 0.005
    Negative   19 (16.7) 13 (12.7)   6 (50.0)
    Positive   95 (83.3) 89 (87.3)   6 (50.0)
HER-2 0.002
    Negative 107 (93.9) 99 (97.1)   8 (66.7)
    Positive   7 (6.1) 3 (2.9)   4 (33.3)
AR 0.515
    Negative   48 (42.1) 44 (43.1)   4 (33.3)
    Positive   66 (57.9) 58 (56.9)   8 (66.7)
Ki-67 LI <0.001
    ≤14   92 (80.7) 88 (86.3)   4 (33.3)
    >14   22 (19.3) 14 (13.7)   8 (66.7)
Molecular type <0.001
    Luminal A   86 (75.4) 83 (81.4)   3 (25.0)
    Luminal B   22 (19.3) 15 (14.7)   7 (58.3)
    HER-2   1 (0.9) 0 (0.0) 1 (8.3)
    TNBC   5 (4.4) 4 (3.9) 1 (8.3)
ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; LI, labeling index; HER-2, human epidermal growth factor receptor-2; TNBC, 
triple-negative breast cancer.
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Impact of expression status for sarcosine metabolism-
related proteins on prognosis in ILC
In ILC, no significant association was found between me-
tabolism-related proteins and prognosis with univariate 
analysis (Table 9). 
DISCUSSION
The purpose of the present study was to investigate and 
compare the expressions of sarcosine metabolism-related 
proteins in ILC and IDC. Compared to IDC, PIPOX had a 
higher expression rate in ILC (p<0.001). Sarcosine meta-
bolic phenotypes, based on expressions of sarcosine metab-
olism-related proteins, were found to have different propor-
tional distributions between ILC and IDC. Low sarcosine 
These different distributions of sarcosine metabolic pheno-
types between IDC and ILC were sustained when com-
pared with the sarcosine metabolic phenotypes in luminal-
type IDC (p<0.001) (Table 8).
Correlation between sarcosine metabolism-related 
proteins and clinicopathologic factors in ILC
In ILC, PIPOX expression was correlated with AR positivi-
ty (p=0.001) (Fig. 2). In the classical type, PIPOX expres-
sion was also correlated with AR positivity (p=0.003), and 
SARDH expression was associated with a higher T stage (p 
=0.004). In the pleomorphic type, SARDH expression was 
correlated with a higher Ki-67 LI (p=0.018) and associated 
with the luminal A molecular type. All SARDH-positive 
cases were luminal A molecular type, and all SARDH-neg-
ative cases were non-luminal A molecular type (p=0.007).
Table 3. Comparison of Clinicopathologic Characteristics between Invasive Lobular Carcinoma and Invasive Ductal Carci-
noma
Parameters Total,n=835 (%)
IDC,
n=721 (%)
ILC,
n=114 (%) p value
Age (yrs) 0.832
    <50 491 (58.8) 428 (59.4)   63 (55.3)
    ≥50 344 (41.2) 293 (40.6)   51 (44.7)
Histologic grade <0.001
    I/II 594 (71.1) 485 (67.3) 109 (95.6)
    III 241 (28.9) 236 (32.7)   5 (4.4)
T stage 0.058
    T1 422 (50.5) 355 (49.2)   67 (58.8)
    T2/T3 413 (49.5) 366 (50.8)   47 (41.2)
Lymph node metastasis 0.026
    Absent 507 (60.7) 427 (59.2)   80 (70.2)
    Present 328 (39.3) 294 (40.8)   34 (29.8)
ER <0.001
    Negative 266 (31.9) 259 (35.9)   7 (6.1)
    Positive 569 (68.1) 462 (64.1) 107 (93.9)
PR <0.001
    Negative 366 (43.8) 347 (48.1)   19 (16.7)
    Positive 469 (56.2) 374 (51.9)   95 (83.3)
HER-2 <0.001
    Negative 672 (80.5) 565 (78.4) 107 (93.9)
    Positive 163 (19.5) 156 (21.6)   7 (6.1)
Ki-67 LI <0.001
    ≤14 501 (60.0) 409 (56.7)   92 (80.7)
    >14 334 (40.0) 312 (43.3)   22 (19.3)
Molecular type <0.001
    Luminal A 389 (46.6) 303 (42.0)   86 (75.4)
    Luminal B 191 (22.9) 169 (23.4)   22 (19.3)
    HER-2 72 (8.6) 71 (9.8)   1 (0.9)
    TNBC 183 (21.9) 178 (24.7)   5 (4.4)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; LI, labeling index; HER-2, human epider-
mal growth factor receptor-2; TNBC, triple-negative breast cancer.
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Table 4. Expressions of Sarcosine Metabolism-Related Proteins in Normal Breast Tissue and ILC 
Parameters Total,n=114 (%)
Normal tissue,
n=30 (%)
ILC
p value†Classic type,
n=102 (%)
Pleomorphic type,
n=12 (%) p value*
GNMT 0.349   0.345
    Negative 107 (93.9)   30 (100.0) 95 (93.1)   12 (100.0)
    Positive   7 (6.1) 0 (0.0) 7 (6.9) 0 (0.0)
SARDH 0.473   0.014
    Negative   94 (82.5)   30 (100.0) 85 (83.3)   9 (75.0)
    Positive   20 (17.5) 0 (0.0) 17 (16.7)   3 (25.0)
PIPOX 0.714 <0.001
    Negative   42 (36.8) 28 (93.3) 37 (36.3)   5 (41.7)
    Positive   72 (63.2) 2 (6.7) 65 (63.7)   7 (58.3)
Sarcosine metabolic type 0.829 <0.001
    High sarcosine type   1 (0.9) 0 (0.0) 1 (1.0) 0 (0.0)
    Intermediate sarcosine type   6 (5.3) 0 (0.0) 6 (5.9) 0 (0.0)
    Low sarcosine type   70 (61.4) 2 (6.7) 62 (60.8)   8 (66.7)
    Null type   37 (32.5) 28 (93.3) 33 (32.4)   4 (33.3)
ILC, invasive lobular carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. 
*Compared between classic type and pleomorphic type.
†Compared between normal tissue and ILC.
Table 5. Expressions of Sarcosine Metabolism-Related Proteins in IDC and ILC
Parameters Total, n=835 (%)
Normal tissue,
n=30 (%)
IDC,
n=721 (%)
ILC,
n=114 (%) p value
GNMT   0.231
    Negative 771 (92.3)   30 (100.0) 664 (92.1) 107 (93.9)
    Positive 64 (7.7) 0 (0.0) 57 (7.9)   7 (6.1)
SARDH   0.045
    Negative 691 (82.8)   30 (100.0) 597 (82.8)   94 (82.5)
    Positive 144 (17.2) 0 (0.0) 124 (17.2)   20 (17.5)
PIPOX <0.001
    Negative 612 (73.3) 28 (93.3) 570 (79.1)   42 (36.8)
    Positive 223 (26.7) 2 (6.7) 151 (20.9)   72 (63.2)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic 
acid oxidase. 
Table 6. Expressions of Sarcosine Metabolism-Related Proteins in ILC and Luminal-Type IDC
Parameters Total,n=586 (%)
IDC, luminal type, 
n=472 (%)
ILC,
n=114 (%) p value
GNMT   0.228
    Negative 533 (91.0) 426 (90.3) 107 (93.9)
    Positive 53 (9.0) 46 (9.7)   7 (6.1)
SARDH   0.923
    Negative 485 (82.8) 391 (82.8)   94 (82.5)
    Positive 101 (17.2)   81 (17.2)   20 (17.5)
PIPOX <0.001
    Negative 410 (70.0) 368 (78.0)   42 (36.8)
    Positive 176 (30.0) 104 (22.0)   72 (63.2)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic 
acid oxidase. 
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Fig. 1. Comparison of sarcosine metabolism-related proteins among normal breast tissue, invasive ductal carcinoma (IDC), and invasive lobular carcinoma 
(ILC). ILC was found to have a higher expression rate of PIPOX than IDC. H&E, hematoxylin and eosin; GNMT, glycine N-methyltransferase; SARDH, sarco-
sine dehydrogenase; PIPOX, l-pipecolic acid oxidase. 
Table 7. Comparison of Sarcosine Metabolic Phenotypes between IDC and ILC
Metabolic phenotypes Total,n=835 (%)
Normal tissue,
n=30 (%)
IDC,
n=721 (%)
ILC,
n=114 (%) p value
Sarcosine metabolic type <0.001
    High sarcosine type 37 (4.4) 0 (0.0) 36 (5.0) 1 (0.9)
    Intermediate type 27 (3.2) 0 (0.0) 21 (2.9) 6 (5.3)
    Low sarcosine type 289 (34.6) 2 (6.7) 219 (30.4) 70 (61.4)
    Null type 482 (57.7) 28 (93.3) 445 (61.7) 37 (32.5)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
Table 8. Comparison of Sarcosine Metabolic Phenotypes between Luminal-Type IDC and ILC
Metabolic phenotypes Total, n=586 (%) IDC, luminal type, n=472 (%) ILC, n=114 (%) p value
Sarcosine metabolic type <0.001
    High sarcosine type 29 (4.9) 28 (5.9) 1 (0.9)
    Intermediate sarcosine type 24 (4.1) 18 (3.8) 6 (5.3)
    Low sarcosine type 217 (37.0) 147 (31.1) 70 (61.4)
    Null type 316 (53.9) 279 (59.1) 37 (32.5)
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
Normal ILC IDC
H&E
GNMT
SARDH
PIPOX
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Although expressions of sarcosine metabolism-related pro-
teins are not yet well-studied in breast cancer, an increased 
sarcosine level has been associated with cancer progression 
in prostate cancer. The addition of exogenous sarcosine was 
reported to induce invasive phenotypes in benign prostate 
type was most common in ILC, whereas null type was most 
common in IDC. In the present study, sarcosine metabo-
lism-related proteins and sarcosine metabolic phenotypes 
were different in ILC and IDC, and there were also clinical 
and histologic distinctions found between ILC and IDC. 
Fig. 2. Correlation between clinicopathologic factors and sarcosine metabolism-related proteins in invasive lobular carcinoma. AR, androgen receptor; 
PIPOX, l-pipecolic acid oxidase; SARDH, sarcosine dehydrogenase; HER-2, human epidermal growth factor receptor-2; TNBC, triple-negative breast cancer.
Table 9. Univariate Analysis by Log-Rank Test of the Impact of Sarcosine Metabolism-Related Protein Expression in Invasive 
Lobular Carcinoma on Disease-Free Survival and Overall Survival Times
Parameters
Disease-free survival Overall survival
95% CI p value 95% CI p value
GNMT N/A N/A
    Negative N/A N/A
    Positive N/A N/A
SARDH N/A 0.538
    Negative N/A   163 (157‒169)
    Positive N/A 91 (83‒98)
PIPOX 0.941 N/A
    Negative   164 (156‒171) N/A
    Positive 93 (89‒96) N/A
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase; CI, confidence interval; N/A, not applicable.
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